Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry

Fig. 2

Multivariate analysis showing the predictors of biologic failure when used in patients with an inadequate response to a first bDMARD (second-line biologic initiation cohort). CI, confidence interval; COX2, cyclooxygenase 2; DAS28-4, disease activity score in 28 joints (four variables); ESR, erythrocyte sedimentation rate

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us